Advertisement

Clinical Immunotherapeutics

, Volume 4, Issue 2, pp 103–123 | Cite as

Effects of Immunosuppressive Agents on Glucose Metabolism

Implications for the Development of Post-Transplant Diabetes Mellitus
  • Andrew J. Krentz
  • Jan Dmitrewski
  • David Mayer
  • Malcolm Nattrass
Adverse Effects and Interactions

Summary

Diabetogenic effects have been ascribed to several drugs currently used for immunosuppression following organ transplantations, including corticosteroids, cyclosporin and tacrolimus (FK-506). Azathioprine appears to be devoid of adverse effects on carbohydrate metabolism.

The pathogenesis of immunosuppression-associated diabetes mellitus has not been clearly defined, and may be multifactorial in organ transplant recipients. Metabolic similarities between post-transplant diabetes and non-insulin-dependent diabetes mellitus include defective insulin secretion and impaired insulin action in target tissues. The predominant effect of corticosteroids is induction of a state of insulin resistance. Cyclosporin and tacrolimus have been shown to inhibit endogenous insulin secretion and may also have adverse effects on tissue sensitivity to insulin.

Postoperative diabetes mellitus developing de novo is a frequent complication of organ transplantation. Treatment with diet, oral antidiabetic agents or insulin may be necessary. Postoperative diabetes may be a transient phenomenon in some patients, whereas others may require long term insulin treatment. Although clinically overt diabetes is readily diagnosed, the prevalence of subclinical degrees of glucose intolerance may be higher than is currently recognised.

The long term clinical implications of immunosuppression-associated glucose intolerance and diabetes are uncertain and rely on extrapolations from studies in non-transplant populations. Patients with impaired glucose tolerance may have an increased probability of progression to diabetes mellitus, whereas long term diabetes carries the risk of tissue damage from specific microvascular complications, i.e. diabetic retinopathy, neuropathy and nephropathy. Epidemiological and experimental studies have implicated glucose intolerance and hyperinsulinaemia as risk factors for atherosclerosis. Hypertension and atherogenic plasma lipid profiles are also frequently encountered in transplant recipients treated with cyclosporin, tacrolimus and corticosteroids. Thus, patients treated with these drugs, particularly in combination, may possess a multiplicity of risk factors for macrovascular disease. These factors may be relevant to the development of accelerated atherosclerosis that occurs in renal and cardiac transplant recipients. However, their contribution to post-transplant macrovascular disease is uncertain at present.

Carefully designed prospective studies will be necessary to determine the natural history of postoperative diabetes in organ transplant recipients. We recommend that future clinical studies of immunosuppressive agents should avoid arbitrary diagnostic criteria for diabetes and should incorporate rigorous methods for the assessment of glucose tolerance, insulin secretion and insulin action. Modifications of existing immunosuppressive drug regimens may reduce the incidence or severity of postoperative diabetes. Elucidation of the molecular mechanisms responsible for this metabolic complication should provide a more logical basis for prevention and treatment.

Keywords

Cyclosporin Insulin Secretion Adis International Limited Tacrolimus Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Starzl TE. Experience in renal transplantation. Philadelphia: WB Saunders, 1964: 116–7Google Scholar
  2. 2.
    Taylor R. Drugs and diabetes mellitus. In: Williams G, Pickup JC, editors. Textbook of diabetes. Oxford: Blackwell Scientific Publications, 1991: 803–8Google Scholar
  3. 3.
    Ferner RE. Drug-induced diabetes. Baillieres Clin Endocrinol Metab 1992; 6: 849–66PubMedCrossRefGoogle Scholar
  4. 4.
    Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725–38PubMedCrossRefGoogle Scholar
  5. 5.
    Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs. cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169–70PubMedGoogle Scholar
  6. 6.
    Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with use of FK 506. Transplant Proc 1991; 23: 3105–8PubMedGoogle Scholar
  7. 7.
    Thomson AW, Nield GH. Cyclosporin: use outside transplantation. BMJ 1991; 302: 4–5PubMedCrossRefGoogle Scholar
  8. 8.
    Nikolaidis NL, Abu-Elmagd K, Thomson AW, et al. Metabolic effects of FK 506 in patients with severe psoriasis: short term follow-up of seven cases. Transplant Proc 1991; 23: 3325–7PubMedGoogle Scholar
  9. 9.
    Herold KC, Rubenstein AH. Immunosuppression for insulindependent diabetes N Engl J Med 1988; 318: 701–3PubMedCrossRefGoogle Scholar
  10. 10.
    Carroll PB, Tzakis AG, Ricordi C, et al. The use of FK 506 in new-onset type 1 diabetes in man. Transplant Proc 1991; 23: 3351–3PubMedGoogle Scholar
  11. 11.
    Sutherland DER. Pancreatic transplantation: an update. Diabetes Rev 1993; 1: 152–65Google Scholar
  12. 12.
    Warnock GL, Kneteman NM, Ryan EA, et al. Long-term follow- up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 89–95PubMedCrossRefGoogle Scholar
  13. 13.
    Krentz AJ, Nattrass M. An introduction to human research. London: The Newbourne Group, 1988: 23–7Google Scholar
  14. 14.
    Elliott MJ, Alberti KGMM. Carbohydrate metabolism — effects of pre-operative starvation and trauma. Clin Anaesthesiol 1983; 1: 527–50Google Scholar
  15. 15.
    Brandi LS, Frediani M, Oleggini M, et al. Insulin resistance after surgery: normalization by insulin treatment. Clin Sci 1990; 79: 443–50PubMedGoogle Scholar
  16. 16.
    National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–57Google Scholar
  17. 17.
    World Health Organization Expert Committee on diabetes mellitus. Technical report series 646. Geneva: World Health Organization, 1980Google Scholar
  18. 18.
    Yudkin JS, Alberti KGMM, McLarty DG, et al. Impaired glucose tolerance. BMJ 1990; 301; 397–402PubMedCrossRefGoogle Scholar
  19. 19.
    Alford FP, Best JD. The aetiology of type 2 diabetes. In: Nattrass M, editor. Recent advances in diabetes 2. Edinburgh: Churchill Livingtone, 1986: 1–22Google Scholar
  20. 20.
    Mak RHK. Renal disease, insulin resistance, and glucose intolerance. Diabetes Rev 1994; 2: 19–28Google Scholar
  21. 21.
    Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967; 2: 1051–6PubMedCrossRefGoogle Scholar
  22. 22.
    Shnueli E, Record Co, Alberti KGMM. Liver disease, carbohydrate metabolism and diabetes. Baillieres Clin Endocrinol Metab 1992; 6: 719–43CrossRefGoogle Scholar
  23. 23.
    Johnston DG, Alberti KGMM, Faber OK, et al. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet 1977; 1: 10–13CrossRefGoogle Scholar
  24. 24.
    Ekstrand A, Ahonen J, Grönhagen-Riska C, et al. Mechanisms of insulin resistance after kidney transplantation. Transplantation 1989; 48: 563–8PubMedGoogle Scholar
  25. 25.
    Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a post receptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131–8PubMedCrossRefGoogle Scholar
  26. 26.
    Perley M, Kipnis DM. Effect of glucocorticooids on plasma insulin. N Engl J Med 1966; 274: 1237–41PubMedCrossRefGoogle Scholar
  27. 27.
    Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983; 72: 1814–20PubMedCrossRefGoogle Scholar
  28. 28.
    Boyle PJ. Cushing’s disease, glucocorticoid excess, glucocorticoid deficiency, and diabetes. Diabetes Rev 1993; 1: 301–8Google Scholar
  29. 29.
    Johnston DG, Pernet A, Nattrass M. Hormonal regulation of fatty acid mobilization in normal and diabetic man. In: Nattrass M, Santiago JV, editors. Recent advances in diabetes 1. Edinburgh: Churchill Livingstone, 1984: 91–106Google Scholar
  30. 30.
    Ruiz JO, Simmons RL, Callender CO, et al. Steroid diabetes in renal transplant recipients: pathogenic factors and prognosis. Surgery 1973; 73: 759–65PubMedGoogle Scholar
  31. 31.
    Hill CM, Douglas JF, Rajkumar KV, et al. Glycosuria and hyperglycaemia after kidney transplantation. Lancet 1974; 2: 490–2PubMedCrossRefGoogle Scholar
  32. 32.
    Woods JE, Zincke H, Palumbo PJ, et al. Hyperosmolar nonketotic syndrome and steroid diabetes: occurrence after renal transplantation. JAMA 1975; 231: 1261–3PubMedCrossRefGoogle Scholar
  33. 33.
    Gunnarsson R, Arner P, Lundgren G, et al. Steroid diabetes after renal transplantation — a preliminary report. Scand J Urol Nephrol 1977; 432: 191–4Google Scholar
  34. 34.
    Gunnarsson R, Arner P, Lundgren G, et al. Diabetes mellitus — a more common than believed complication of renal transplantation. Transplant Proc 1979; 11: 1280–1PubMedGoogle Scholar
  35. 35.
    McGeown M, Douglas F, Brown W, et al. Advantages of low-dose steroid from the day after renal transplantation. Transplantation 1980; 229: 287–9CrossRefGoogle Scholar
  36. 36.
    David DS, Cheigh JS, Braun DW, et al. HLA-A28 and steroid-induced diabetes in renal transplant recipients. JAMA 1980; 243: 532–3PubMedCrossRefGoogle Scholar
  37. 37.
    Arner P, Gunnarsson R, Blomdahl S, et al. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983; 6: 23–25PubMedCrossRefGoogle Scholar
  38. 38.
    Friedman EA, Shyh T, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196–202PubMedCrossRefGoogle Scholar
  39. 39.
    Krentz AJ. Diabetic ketoacidosis, hyperosmolar non-ketotic coma and lactic acidosis. In: Foex P, Garrad C, Westaby S, editors. Principles and practice of critical care. Oxford: Blackwell Scientific. In pressGoogle Scholar
  40. 40.
    D’Apice AJF, Mathews JD, Tait BD, et al. Association of HLA-antigens with glucose tolerance following renal transplantation. Tissue Antigens 1978; 11: 423–6PubMedCrossRefGoogle Scholar
  41. 41.
    Hricik DE, Almawi WY, Strom TB. Trends in the use of corticosteroids in renal transplantation. Transplantation 1994; 57: 979–89PubMedGoogle Scholar
  42. 42.
    Collier StJ, Calne R. Practical problems in immunosuppression: kidney and liver transplants. Prescribers J 1991; 31: 122–7Google Scholar
  43. 43.
    Padbury RTA, Gunnson BK, Dousset B, et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789–94PubMedCrossRefGoogle Scholar
  44. 44.
    Ratcliffe PJ, Firth JD, Higgins RM, et al. Randomized controlled trial of complete steroid withdrawal in renal transplant patients receiving triple immunosuppression. Transplant Proc 1993; 25: 590PubMedGoogle Scholar
  45. 45.
    European Multicentre Trial Group. European multicentre trial of cyclosporin in renal transplantation: 10-year follow-up. Transplant Proc 1993; 25: 527–9Google Scholar
  46. 46.
    Gunnarson R, Klintmalm G, Lundgren G, et al. Deterioration in glucose metabolism in pancreatic transplant patients given cyclosporine [letter]. Lancet 1983; 2: 571–2CrossRefGoogle Scholar
  47. 47.
    Engfeldt P, Tyden G, Gunnarson R, et al. Impaired glucose tolerance with cyclosporine. Transplant Proc 1986; 18: 65–6Google Scholar
  48. 48.
    Harris KPG, Russell, Parvin SD, et al. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. BMJ 1986; 292: 16PubMedCrossRefGoogle Scholar
  49. 49.
    Binder C. C-peptide and B-cell function. In: Williams G, Pickup JC, editors. Textbook of diabetes. Oxford: Blackwell Scientific, 1991: 348–54Google Scholar
  50. 50.
    Ost L. Effects of cyclosporin on prednisolone metabolism [letter]. Lancet 1984; 1: 451PubMedCrossRefGoogle Scholar
  51. 51.
    Yagisawa T, Takahashi K, Teraoka S, et al. Deterioration in glucose metabolism in cyclosporine treated kidney transplant recipients and rats. Transplant Proc 1986; 18: 1548–51Google Scholar
  52. 52.
    Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376–81PubMedCrossRefGoogle Scholar
  53. 53.
    Kahan BD, Flechner SM, Lorber MI, et al. Complications of cyclosporine-prednisolone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 1987; 43: 197–204PubMedCrossRefGoogle Scholar
  54. 54.
    Ost L, Tynden G, Fehrman I. Impaired glucose tolerance in cyclosporin-prednisolone-treated renal graft recipients. Transplantation 1988; 46: 370–2PubMedCrossRefGoogle Scholar
  55. 55.
    Nakai I, Omori Y, Aikawa I, et al. Effects of cyclosporine on glucose metabolism in kidney transplant recipients. Transplant Proc 1988; 20Suppl. 3: 969–78PubMedGoogle Scholar
  56. 56.
    Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12: 11–7PubMedGoogle Scholar
  57. 57.
    Mejia G, Arbelaez M, Henao JE, et al. Cyclosporine-associated diabetes mellitus in renal transplants. Clin Transpl 1989; 3: 260–3Google Scholar
  58. 58.
    Roth D, Milgrom M, Esqeunazi V, et al. Posttransplant hyperglycemia: increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989; 47: 278–81PubMedCrossRefGoogle Scholar
  59. 59.
    Von Kiparksi A, Frei D, Uhlschmid G, et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol Dial Transplant 1990; 5: 220–5CrossRefGoogle Scholar
  60. 60.
    Yamamoto H, Akazawa S, Yagamuchi Y, et al. Effects of cyclosporin A and low dosages of steroid on post-transplantation diabetes in kidney transplant recipients. Diabetes Care 1991; 14: 867–70PubMedCrossRefGoogle Scholar
  61. 61.
    Sumrani NB, Delany V, Ding Z, et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991; 51: 343–7PubMedCrossRefGoogle Scholar
  62. 62.
    Rao M, Jacob CK, Shastry JCM. Post-renal transplant diabetes mellitus — a retrospective study. Nephrol Dial Transplant 1992; 7: 1039–42PubMedGoogle Scholar
  63. 63.
    Basri N, Aman H, Adiku W, et al. Diabetes mellitus after renal transplantation. Transplant Proc 1992; 24: 1780–1PubMedGoogle Scholar
  64. 64.
    Prasad TN, Prakash BS, Subramanyam K, et al. Post-renal transplant diabetes in conventional and cyclosporine regimes. Transplant Proc 1992; 24: 1728Google Scholar
  65. 65.
    Fryer JP, Granger DK, Leventhal JR, et al. Steroid-related complications in the cyclosporine era. Clin Transplantation 1994; 8: 224–9Google Scholar
  66. 66.
    Harris MI. Diabetes in Hispanics, Whites and Blacks in the US population: epidemiologic correlates. Diabetes Care 1991; 14Suppl. 3: 39–48Google Scholar
  67. 67.
    Ekstrand AV, Eriksson JG, Gronhagen-Riska C, et al. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 1992; 53: 563–9PubMedCrossRefGoogle Scholar
  68. 68.
    Yamasaki Y, Takahashi K, Yagisawa T, et al. Alterations in glucose tolerance and insulin release in renal transplant recipients receiving cyclosporine and corticosteroids. Transplant Proc 1988; 20Suppl. 1: 158–9Google Scholar
  69. 69.
    Bending JJ, Ogg CS, Viberti GC. Diabetogenic effect of cyclosporine. BMJ 1987; 294: 410–1CrossRefGoogle Scholar
  70. 70.
    Blackman JD, Polonsky KS, Jaspan JB, et al. Insulin secretory profiles and C-peptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes 1992; 41: 1346–52PubMedCrossRefGoogle Scholar
  71. 71.
    Luzi L, Secchi A, Facchini F, et al. Reduction of insulin resistance by combined kidney-pancreas transplantation in type 1 (insulin-dependent) diabetic patients. Diabetologia 1990; 33: 549–56PubMedCrossRefGoogle Scholar
  72. 72.
    Robertson RP. Pancreas transplantation in humans with diabetes mellitus. Diabetes 1991; 40: 1085–9PubMedCrossRefGoogle Scholar
  73. 73.
    Radziuk J, Barron P, Najm H, et al. The effect of systemic venous drainage of the pancreas on insulin sensitivity in dogs. J Clin Invest 1993; 93: 1713–21CrossRefGoogle Scholar
  74. 74.
    Yki-Jarvinen H. Pathogenesis of non-insulin-dependent diabetes. Lancet 1994; 343: 91–5PubMedCrossRefGoogle Scholar
  75. 75.
    Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 327: 707–13Google Scholar
  76. 76.
    Temple R, Clark PMS, Hales CN. Measurement of insulin secretion in type 2 diabetes. Problems and pitfalls. Diabetic Med 1992; 9: 503–12PubMedCrossRefGoogle Scholar
  77. 77.
    Esmatjes E, Ricart MJ, Ferrer JP, et al. Cyclosporin’s effect on insulin secretion in patients with kidney transplants. Transplantation 1991; 52: 500–3PubMedCrossRefGoogle Scholar
  78. 78.
    Ward WK, LaCava EC, Paquette TL, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698–702PubMedCrossRefGoogle Scholar
  79. 79.
    Garvin PJ, Niehoff M, Staggenborg J. Cyclosporine’s effect on canine pancreatic endocrine function. Transplantation 1988; 45: 1027–31PubMedCrossRefGoogle Scholar
  80. 80.
    Yale J-F, Chamelian M, Courschesne S, et al. Peripheral insulin resistance and decreased insulin secretion after cyclosporine treatment. Transplant Proc 1988; 20Suppl. 3: 985–8PubMedGoogle Scholar
  81. 81.
    Alejandro R, Feldman EC, Bloom AD, et al. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 1989; 38: 698–703PubMedCrossRefGoogle Scholar
  82. 82.
    Dresner LS, Andersen DK, Kahng KU, et al. Effects of cyclosporine on glucose metabolism. Surgery 1989; 106: 163–70PubMedGoogle Scholar
  83. 83.
    Riegel W, Brehmer D, Thaiss F, et al. Effect of cyclosporin A on carbohydrate metabolism in the rat. Transpl Int 1989; 2: 8–12PubMedCrossRefGoogle Scholar
  84. 84.
    Wahlstrom HE, Akimoto R, Endres D, et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short term cyclosporin treatment. Transplantation 1992; 53: 1190–5PubMedCrossRefGoogle Scholar
  85. 85.
    Helmchen U, Schmidt WE, Siegel EG, et al. Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia 1984; 27: 416–8PubMedCrossRefGoogle Scholar
  86. 86.
    Andersson A, Borg H, Hallberg A, et al. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 1984; 27: 66–9PubMedCrossRefGoogle Scholar
  87. 87.
    Robertson RP. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 1986; 35: 1016–9PubMedCrossRefGoogle Scholar
  88. 88.
    Hahn HJ, Dunger A, Laube F, et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 1986; 29: 489–94PubMedCrossRefGoogle Scholar
  89. 89.
    Eun H-M, Pak C-Y, Kim C-J, et al. Role of cyclosporin A in macromolecular synthesis of B-cells. Diabetes 1987; 36: 952–8PubMedCrossRefGoogle Scholar
  90. 90.
    Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986; 35: 1049–52PubMedCrossRefGoogle Scholar
  91. 91.
    Chandrasekar B, Mukherjee SK. Effect of prolonged administration of cyclosporin A on (pro)insulin biosynthesis and insulin release by rat islets of Langerhans. Biochem Pharmacol 1988; 37: 3609–11PubMedCrossRefGoogle Scholar
  92. 92.
    Gillison SL, Bartlett ST, Curry DL. Synthesis-secretion coupling of insulin: effect of cyclosporin. Diabetes 1989; 38: 465–70PubMedCrossRefGoogle Scholar
  93. 93.
    Gillison SL, Bartlett ST, Curry DL. Inhibition by cyclosporine of insulin secretion — a beta cell-specific alteration of islet tissue function. Transplantation 1991; 52: 890–5PubMedCrossRefGoogle Scholar
  94. 94.
    Sestior C, Odert-Pogo S, Bonneville M, et al. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol Lett 1985; 10: 57–60CrossRefGoogle Scholar
  95. 95.
    Pollock SM, Reichbaum MI, Collies BM, et al. Inhibitory effect of cyclosporin A on the activity of oral hypoglycemic agents in rats. J Pharmacol Exp Ther 1991; 258: 8–12PubMedGoogle Scholar
  96. 96.
    Runzi M, Peskar BM, von Schonfield S, et al. Importance of endogenous prostaglandins for the toxicity of cyclosporin A to rat endocrine and exocrine pancreas. Gut 1992; 33: 1572–7PubMedCrossRefGoogle Scholar
  97. 97.
    Muller MK, Wojzck M, Runzi M, et al. Cytoprotection and dose-dependent inhibitory effects of prostaglandin E1 on rat pancreas treated with cyclosporin A. Digestion 1991; 50: 29–36Google Scholar
  98. 98.
    Robertson RP, Franklin G, Nelson L. Intravenous glucose tolerance and pancreatic islet beta-cell function in patients with multiple sclerosis during 2-yr treatment with cyclosporin. Diabetes 1989; 38: 58–64PubMedCrossRefGoogle Scholar
  99. 99.
    Teuscher AU, Sequist ER, Robertson RP. Diminished secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 1994; 43: 593–8PubMedCrossRefGoogle Scholar
  100. 100.
    Starzl TE, Todo S, Fung T, et al. FK506 for liver, kidney, and pancreatic transplantation. Lancet 1989; 2: 1000–4PubMedCrossRefGoogle Scholar
  101. 101.
    Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990; 212: 295–305PubMedCrossRefGoogle Scholar
  102. 102.
    Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK 506. JAMA 1990; 264: 63–7PubMedCrossRefGoogle Scholar
  103. 103.
    Mieles L, Todo S, Fung JJ, et al. Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc 1990; 22: 41–3PubMedGoogle Scholar
  104. 104.
    Mieles L, Gordon RD, Mintz D, et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Tranplant Proc 1991; 23: 949–53Google Scholar
  105. 105.
    Carroll PB, Rilo H, Reyes J, et al. FK 506-associated diabetes in the pediatric population is a rare complication. Transplant Proc 1991; 23: 3171–2PubMedGoogle Scholar
  106. 106.
    Tabasco-Minguillan J, Mieles L, Carroll P, et al. Long-term insulin requirement after liver transplantation in American veterans. Transplant Proc 1993; 25: 677–8PubMedGoogle Scholar
  107. 107.
    Tabasco-Minguillan J, Mieles L, Carroll P, et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. Transplantation 1993; 56: 862–7PubMedCrossRefGoogle Scholar
  108. 108.
    Ericzon B, Groth C, Bismuth H, et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. Transpl Int 1994; 7Suppl. 1: S11–4PubMedCrossRefGoogle Scholar
  109. 109.
    European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8Google Scholar
  110. 110.
    O’Grady JG, Forbes A, Rolles K, et al. An analysis of cyclosporine efficacy and toxicity after liver transplantation. Transplantation 1988; 45: 575–9PubMedCrossRefGoogle Scholar
  111. 111.
    Krentz AJ, Dousset B, Mayer D, et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 1993; 42: 1753–9PubMedCrossRefGoogle Scholar
  112. 112.
    Krentz AJ, Dmitrewski J, Mayer AD, et al. Postoperative glucose metabolism in liver transplant recipients: a two year randomized prospective study of cyclosporine versus FK 506. Transplantation 1994; 57: 1666–9PubMedGoogle Scholar
  113. 113.
    Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporinetreated transplant recipients. Transplantation 1991; 51: 374–7PubMedCrossRefGoogle Scholar
  114. 114.
    Jindal RM, Popescu I, Schwartz ME, et al. Diabetogenicity of FK506 versus cyclosporin in liver transplant recipients. Transplantation 1994; 58: 370–2PubMedGoogle Scholar
  115. 115.
    The US Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110–5Google Scholar
  116. 116.
    Collins RH. Tacrolimus (FK 506) versus cyclosporin in prevention of liver allograft rejection [letter]. Lancet 1994; 344: 949PubMedCrossRefGoogle Scholar
  117. 117.
    Bone AJ, Walker R, Varey A-M, et al. Effect of cyclosporin on pancreatic events and development of diabetes in BB/ Edinburgh rats. Diabetes 1990; 39: 508–14PubMedCrossRefGoogle Scholar
  118. 118.
    Murase N, Lieberman I, Nalesnik MA, et al. Effect of FK506 on spontaneous diabetes in BB rats. Diabetes 1990; 39: 1584–6PubMedCrossRefGoogle Scholar
  119. 119.
    Collier DStJ, Calne R, Thiru S, et al. FK-506 in experimental renal allografts. Transplant Proc 1987; 19: 3975–7PubMedGoogle Scholar
  120. 120.
    Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693–9PubMedCrossRefGoogle Scholar
  121. 121.
    Strasser S, Alejandro R, Ricordi C, et al. The effect of FK 506 on canine pancreatic islet function in beagle dogs. Transplant Proc 1991; 23: 756–7PubMedGoogle Scholar
  122. 122.
    Ericzon B-G, Wijnen RMH, Kubota K, et al. FK 506-induced impairment of glucose metabolism in the primate — studies in pancreatic transplant recipients and non-transplanted animals. Transplantation 1992; 54: 615–20PubMedCrossRefGoogle Scholar
  123. 123.
    Tze WJ, Tai J, Cheung S. In vitro effects of FK-506 on human and rat islets. Transplantation 1990; 49: 1172–4PubMedCrossRefGoogle Scholar
  124. 124.
    Carroll PB, Boschero AC, Li M-Y, et al. Effect of the immunosuppressant FK 506 on glucose-induced insulin secretion from adult rat islets of langerhans. Transplantation 1991; 51: 275–8PubMedCrossRefGoogle Scholar
  125. 125.
    Ricordi C, Zeng Y, Alejandro R, et al. In vivo effect of FK 506 on human pancreatic islets. Transplantation 1991; 52: 519–22PubMedCrossRefGoogle Scholar
  126. 126.
    Rilo HLR, Zeng R, Alejandro R, et al. Effect of FK 506 on function of human islets of langerhans. Transplant Proc 1991; 23:3164–5PubMedGoogle Scholar
  127. 127.
    Tze WJ, Tai J, Murase N, et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc 1991; 23: 3158–60PubMedGoogle Scholar
  128. 128.
    Ishizuki J, Gugliuzza KK, Wassmuth Z, et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 1993; 56: 1486–90CrossRefGoogle Scholar
  129. 129.
    Hirano Y, Fujihira S, Ohara K, et al. Morphological and functional changes of islets of langerhans in FK506-treated rats. Transplantation 1992; 53: 889–94PubMedCrossRefGoogle Scholar
  130. 130.
    Haba T, Hachisuka T, Ohtsuka S, et al. Pathological and immunohistochemical examination in the rat treated with FK 506. Transplant Proc 1991; 23: 2229–32PubMedGoogle Scholar
  131. 131.
    Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Immunol Today 1992; 13: 136–42PubMedCrossRefGoogle Scholar
  132. 132.
    Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK 506 and cyclosporin. Ann NY Acad Sci 1993; 696: 9–19PubMedCrossRefGoogle Scholar
  133. 133.
    Howell SL. Insulin biosynthesis and secretion. In: Williams G, Pickup JC, editors. Textbook of diabetes. Oxford: Blackwell Scientific, 1991: 72–83Google Scholar
  134. 134.
    Rasmussen H, Zawalich KC, Ganesan S, et al. Physiology and pathophysiology of insulin secretion. Diabetes Care 1990; 13: 655–66PubMedCrossRefGoogle Scholar
  135. 135.
    Rhodes CJ, Alarcon C. What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Diabetes 1994; 43: 511–7PubMedCrossRefGoogle Scholar
  136. 136.
    Draznin B, Metz SA, Sussman KE, et al. Cyclosporin-induced inhibition of isnulin release: possible role of voltage-dependent calcium transport channels. Biochem Pharmacol 1988; 37: 3941–5PubMedCrossRefGoogle Scholar
  137. 137.
    Martin F, Bedoya FJ. Mechanisms of action of cyclosporin A on islet alpha- and beta-cells. Effects of cAMP- and calcium-dependent pathways. Life Sci 1991; 39: 1915–21CrossRefGoogle Scholar
  138. 138.
    Bartlett ST, Gillison SL, Curry DL. Cyclosporine inhibition of insulin secretion: effect of tolbutamide and extracellular calcium concentration. Transplant Proc 1990; 22: 749–53PubMedGoogle Scholar
  139. 139.
    Saltiel AR. Second messengers of insulin action. Diabetes Care 1990; 13: 244–56PubMedCrossRefGoogle Scholar
  140. 140.
    Hotamisligil GS, Spiegelman BM. Tumour necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271–8PubMedCrossRefGoogle Scholar
  141. 141.
    Jindal RM. Posttransplant diabetes mellitus — a review. Transplantation 1994; 58: 1289–98PubMedGoogle Scholar
  142. 142.
    Krentz AJ, Dmitrewski J, Mayer D, et al. Tacrolimus (FK 506) versus cyclosporin in prevention of liver allograft rejection [letter]. Lancet 1994; 344: 948–9PubMedCrossRefGoogle Scholar
  143. 143.
    Krentz AJ, Singh BM, Hale PJ, et al. Basal intermediary metabolism in impaired glucose tolerance and morbid obesity. Diabetes Res 1992; 20: 51–60PubMedGoogle Scholar
  144. 144.
    Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676–85PubMedCrossRefGoogle Scholar
  145. 145.
    Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123–31PubMedCrossRefGoogle Scholar
  146. 146.
    Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365–76PubMedCrossRefGoogle Scholar
  147. 147.
    Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporin and prednisolone. Circulation 1987; 76: 827–34PubMedCrossRefGoogle Scholar
  148. 148.
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607PubMedCrossRefGoogle Scholar
  149. 149.
    DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94PubMedCrossRefGoogle Scholar
  150. 150.
    Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med 1988; 85: 131–3PubMedCrossRefGoogle Scholar
  151. 151.
    Editorial. Hyperlipidaemia after renal transplantation. Lancet 1988; 1: 919–20Google Scholar
  152. 152.
    Barbir M, Kushwaha S, Hunt B, et al. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant patients. Lancet 1992; 340: 1500–2PubMedCrossRefGoogle Scholar
  153. 153.
    Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53–6PubMedCrossRefGoogle Scholar
  154. 154.
    Krentz AJ, Cramb R, Douset B, et al. Serum lipids and apolipoproteins in liver transplant recipients: a comparative study of cyclosporin A and FK 506. J Lab Clin Med 1994; 124: 381–5PubMedGoogle Scholar
  155. 155.
    Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporin versus FK506. Transplantation 1994; 57: 1395–8PubMedCrossRefGoogle Scholar
  156. 156.
    Oplez G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443–6CrossRefGoogle Scholar
  157. 157.
    Hollander AAMJ, van Saase JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610–4PubMedCrossRefGoogle Scholar
  158. 158.
    Schleibner S, Krauss M, Wagner K, et al. FK 506 versus cyclosporin in the prevention of renal allograft rejection — European pilot study: six week results. Transpl Int 1995; 8: 86–90PubMedGoogle Scholar
  159. 159.
    Schlitt HJ, Pilchmayr R. Increasing the long-term success of renal transplantation. Lancet 1995; 345: 600–1PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Andrew J. Krentz
    • 1
  • Jan Dmitrewski
    • 2
  • David Mayer
    • 2
  • Malcolm Nattrass
    • 1
  1. 1.Diabetes Resource Centre, The General HospitalBirminghamEngland
  2. 2.Liver UnitQueen Elizabeth HospitalBirminghamEngland

Personalised recommendations